I Was Right: President Trump Will Legalize Marijuana in 2026

President Trump signed an executive order rescheduling marijuana from Schedule I to Schedule III, a move that does not legalize cannabis but could permit Medicare coverage for certain CBD treatments and enable marijuana businesses to claim ordinary tax deductions. The change is expected to reduce costs for cannabis operators, increase banking access, and likely boost demand and revenues; Tilray announced a U.S. medical subsidiary (Tilray Medical USA) while Aurora and Canopy have not yet commented. Analysts cited expect Aurora may reach GAAP profitability next year, Canopy non-GAAP profitability, and Tilray is already non-GAAP profitable, underpinning a constructive outlook for cannabis equities should rescheduling pave the way for broader legalization in 2026.

Analysis

Market structure: Rescheduling to Schedule III materially lowers compliance friction: expect immediate margin tailwinds from 280E relief (if IRS interprets consistently) and banking access within 3–12 months, compressing cost of capital by an estimated 200–600 bps for US operations. Winners: vertically integrated producers and cross‑border operators (Tilray/TLRY) and cannabis-friendly regional banks; losers: cash/AML-exposed cash-handling service providers and premium boutique brands facing price competition. Competitive dynamics: easier tax treatment + banking will favor scale — national MSOs and companies with US supply chains should gain share while small illicit/fragmented incumbents face price-driven consolidation over 12–36 months.

Risk assessment: Tail risks include judicial reversal, Congress blocking statutory change, or IRS/DEA delaying implementation — any of which could wipe 20–50% off re-rating expectations. Short horizon (days–weeks): volatile equity repricing and IV spikes around statements (State of the Union, IRS memo); medium (3–12 months): margin realization depends on formal tax guidance; long (>12 months): full legalization or congressional action could expand addressable market >2x and attract M&A. Hidden dependencies: bank risk models, insurance availability, and state-to-state regulatory mismatches will govern real funding; absence of clear IRS rules is the single biggest gating factor.

trade implications: Establish a tactical overweight in TLRY (proactive US unit) sized 2–3% of equity portfolio within 2–6 weeks to capture first-mover premium, paired with a 25–35% take-profit band or catalyst exit (IRS guidance or Jan 2026 SOTU). Implement a pair trade: long TLRY (2%) / short CGC (1.25%) to express execution dispersion — TLRY likely to re-rate faster than Canopy given US foothold. Use defined-risk options: buy 9–12 month TLRY call spreads 30% OTM (max loss = premium) to leverage regulatory realization while capping downside; size total option exposure to <1% notional.

contrarian angles: Consensus assumes linear margin improvement; markets underprice risk that wider legalization will intensify price competition and compress per‑unit revenues by 10–25% as supply scales. Historical parallels (alcohol repeal, pharma rescheduling) show multi-year dispersion before stable pricing — if IRS/DEA stagger guidance, expect a two‑step rally then mean reversion. Unintended consequences include higher SG&A for compliance and KYC that could offset tax gains; if banks impose stringent covenants, working capital benefits may be muted.

Key Decisions for Investors

• Establish a 2–3% long position in Tilray Brands (TLRY) within 2–6 weeks to capture first‑mover advantage from its announced U.S. subsidiary; set tactical targets to take 30–50% profits on confirmed IRS guidance or within 9–12 months, and a stop at 30% loss if no regulatory milestones in 90 days.
• Implement a relative value pair: long TLRY (2% weight) and short Canopy Growth (CGC) at 1.25% weight to express execution/catalyst dispersion; reassess after IRS/DEA/State of the Union windows (60–120 days) and close if pair fails to move >=15% in either direction.
• Buy 9–12 month TLRY call spreads (buy calls ~30% OTM, sell calls ~60% OTM) size <=1% portfolio notional to leverage rescheduling while capping downside; roll or take profits on a 50% option-premium gain or after regulatory confirmation events.
• Add a smaller opportunistic long in Aurora Cannabis (ACB) at 1–1.5% for potential near-term GAAP profitability catalyst; use a 25% stop-loss and exit if quarterly filings miss revenue/margin guidance or if IRS guidance negates expected tax relief.
• Trigger/monitor rules: if IRS issues clear 280E relief within 60 days, add 50% to TLRY position and trim short CGC exposure; if IRS/DEA delay >120 days or courts stay the EO, reduce cannabis equity exposure by 50% and shift to select regional banks likely to win new deposit flow (reassess names after bank earnings).